OpGen (OPGN) Getting Somewhat Positive Media Coverage, Report Finds

News coverage about OpGen (NASDAQ:OPGN) has been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. OpGen earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned media headlines about the medical research company an impact score of 46.4749380854252 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

A number of equities research analysts recently weighed in on the company. Zacks Investment Research cut OpGen from a “buy” rating to a “hold” rating in a report on Wednesday, September 13th. HC Wainwright reissued a “buy” rating and issued a $1.00 target price on shares of OpGen in a research note on Monday, September 11th. Finally, Dawson James reissued a “buy” rating on shares of OpGen in a research note on Monday, June 19th.

OpGen (NASDAQ:OPGN) traded down 2.94% on Tuesday, hitting $0.31. The stock had a trading volume of 351,601 shares. OpGen has a 12-month low of $0.21 and a 12-month high of $3.10. The company’s market capitalization is $15.98 million. The company has a 50 day moving average of $0.30 and a 200 day moving average of $0.30.

WARNING: This piece of content was reported by BBNS and is owned by of BBNS. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://baseballnewssource.com/markets/opgen-opgn-getting-somewhat-favorable-press-coverage-report-shows/1699516.html.

OpGen Company Profile

OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.

Insider Buying and Selling by Quarter for OpGen (NASDAQ:OPGN)

Receive News & Ratings for OpGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1


Leave a Reply

 
© 2006-2017 BBNS.